This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer, Moderna Support COVID Vaccine Booster Before FDA Meet
by Zacks Equity Research
Amid rising coronavirus cases, PFE and MRNA are trying to make booster doses of their COVID-19 vaccine available for US citizens. An FDA meeting is scheduled tomorrow to discuss Comirnaty's booster dose.
The Zacks Analyst Blog Highlights: Pfizer, HP, Kohl's, Macy's, LKQ and United States Steel
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, HP, Kohl's, Macy's, LKQ and United States Steel
Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA Acceptance
by Zacks Equity Research
Axsome (AXSM) is seeking approval for its key pipeline candidate, AXS-07, as a potential acute treatment for migraine.
Markets Melt Down on Profit Taking, Not Economic Logic: 5 Picks
by Nalak Das
We have narrow down the search to five stocks that have provided double-digit returns year to date. These are: HPQ, LKQ, KSS, M and X.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $44.71, marking a +0.29% move from the previous day.
DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study
by Zacks Equity Research
DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurrent stroke.
5 Top-Ranked Large-Cap Stocks That Have Skyrocketed YTD
by Nalak Das
We have narrowed down our search to five large-cap stocks with strong potential for the rest of 2021. These are: NUE, ON, KMX, ORLY and ULTA.
Novavax (NVAX) Stock Surges YTD as COVID Vaccine Advances Well
by Zacks Equity Research
Upon approval and successful commercialization, Novavax's (NVAX) COVID-19 vaccine should reap huge revenues. The company's other pipeline candidates also show promise.
Will COVID-19 Vaccines for Children be Available by Year-End?
by Zacks Equity Research
The FDA is trying to make available a safe and effective COVID-19 vaccine for use in children below 12 years of age as soon as possible.
Why U.S. Airline Stocks Gained Yesterday Despite Dim Views
by Maharathi Basu
Stocks like Delta (DAL), American Airlines (AAL) and Southwest (LUV) gain on Thursday despite the Delta variant-induced dull warnings.
Decoding Mu Variant: The Next Big Threat in COVID-19 Cases?
by Zacks Equity Research
Another variant of the coronavirus, Mu Variant, is up on the WHO-identified list. One study finds its potential to be highly resistant to the COVID-19 vaccines.
ETFs in Focus on Airlines' Slowdown Warnings
by Sweta Killa
The slew of revenue warnings comes with signs of recovery, thereby leading to spike in airline stocks.
Myovant (MYOV), Pfizer sNDA for Myfembree Accepted by the FDA
by Zacks Equity Research
Myovant's (MYOV) application for the label expansion of Myfembree gets accepted by the FDA for the indication of pain associated with endometriosis.
Pharma Stock Roundup: SNY to Buy Kadmon, New Approvals for AZN & MRK's Drugs
by Kinjel Shah
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business. AstraZeneca's (AZN) Ultomiris and Merck's (MRK) Keytruda get approvals for expanded use.
Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMC
Erasca (ERAS) Inks Deal With Pfizer for Colorectal Cancer Study
by Zacks Equity Research
Erasca (ERAS) signs an agreement with Pfizer for a clinical study, which will evaluate ERAS-007 in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer.
Novavax (NVAX) Begins Clinical Study on COVID/Flu Combo Jab
by Zacks Equity Research
Novavax (NVAX) starts enrolling patients in a phase I/II study to evaluate a combination of its COVID vaccine and seasonal influenza vaccine.
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $46.51 in the latest trading session, marking a -0.51% move from the prior day.
Tap the Nasdaq Rally With These Two Leveraged ETFs
by Sweta Killa
Investors could easily tap the bullish trend by considering a near-term long on the Nasdaq Index with the help of ETFs.
Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study
by Zacks Equity Research
Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.
Merck's (MRK) Keytruda Gets Nod for Expanded Use in China
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in combination with chemotherapy in the first-line setting for advanced esophageal and GEJ cancer in China based on data from the phase III KEYNOTE-590 study.
Moderna (MRNA) Inks Deal to Develop Ultra-Rare Disease Therapy
by Zacks Equity Research
Moderna (MRNA) inks a collaboration deal with the Institute for Life Changing Medicines to develop a free of charge mRNA-based therapy to treat Crigler-Najjar Syndrome type 1, an ultra-rare disease.
Zacks Industry Outlook Highlights: Johnson & Johnson, Roche, Pfizer and AstraZeneca
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Roche, Pfizer and AstraZeneca
4 Big Drugmaker Stocks to Watch Out For as Recovery Gains Steam
by Kinjel Shah
Most Large Cap Pharmaceuticals industry players' Q2 results were strong. Regulatory/pipeline updates related to COVID-19 medicines/vaccines continue to take center stage. JNJ, RHHBY, PFE and AZN are worth retaining in your portfolio.
Moderna (MRNA) Seeks Authorization for Booster Dose in Europe
by Zacks Equity Research
Moderna (MRNA) is developing a booster dose of its COVID-19 vaccine, mRNA-1273, for enhancing protection against infection in individuals.